CTI BioPharma to Participate in Upcoming Investor Conferences in February 2023

CTI BioPharma Corp. (Nasdaq: CTIC) will engage in a Fireside Chat at two prominent investor conferences in February 2023.

Rhea-AI Summary

CTI BioPharma Corp. (Nasdaq: CTIC) will engage in a Fireside Chat at two prominent investor conferences in February 2023. The first is the Guggenheim Partners 5th Annual Oncology Conference on February 8, 2023, at 10:45 a.m. ET in New York, NY. The second is the SVB Securities Global Biopharma Conference on February 15, 2023, at 3:40 p.m. ET, conducted virtually. Both events will be live-streamed and available for replay on CTI BioPharma's website. The company specializes in targeted therapies for blood-related cancers and has one FDA-approved product, VONJO™, for treating myelofibrosis in certain patient populations.

Argus Session date unavailable

+2.68% session move Open Argus

Details

News Market Reaction – CTIC

The recorded move for CTIC in the trading session of this news was +2.68%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEATTLE, Feb. 2, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced that senior leadership will participate in a Fireside Chat at the following investor conferences in February 2023:

Guggenheim Partners 5th Annual Oncology Conference
Wednesday, February 8, 2023
10:45 a.m. ET
New York, NY

SVB Securities Global Biopharma Conference
Wednesday, February 15, 2023
3:40 p.m. ET
Virtual

The presentations will be webcast live and available for replay from the Investors section of CTI BioPharma's website at www.ctibiopharma.com.

About CTI BioPharma Corp.

We are a commercial biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI has one FDA-approved product VONJO™ (pacritinib), a JAK2 and IRAK1, that spares JAK1. VONJO is approved for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 10⁹/L. CTI is conducting the Phase 3 PACIFICA study of VONJO in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement.

VONJO™ is a trademark of CTI BioPharma Corp.

Investor Relations and Media Contacts:

Remy Bernarda
Jenny Kobin
invest@ctibiopharma.com 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/cti-biopharma-to-participate-in-upcoming-investor-conferences-in-february-2023-301737063.html

SOURCE CTI BioPharma Corp.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is CTI BioPharma participating in the Guggenheim Partners Oncology Conference?

CTI BioPharma will participate in the Guggenheim Partners 5th Annual Oncology Conference on February 8, 2023, at 10:45 a.m. ET in New York, NY.

What is the date and time for CTI BioPharma's participation in the SVB Securities Biopharma Conference?

CTI BioPharma will participate in the SVB Securities Global Biopharma Conference on February 15, 2023, at 3:40 p.m. ET, which will be held virtually.

How can I watch the presentations from CTI BioPharma's investor conferences?

The presentations will be webcast live and available for replay from the Investors section of CTI BioPharma's website.

What is VONJO™ and its approval status?

VONJO™ (pacritinib) is an FDA-approved treatment for adults with intermediate or high-risk myelofibrosis, specifically for those with a platelet count below 50 × 10⁹/L.

What ongoing study is CTI BioPharma conducting related to VONJO™?

CTI BioPharma is conducting the Phase 3 PACIFICA study of VONJO™ in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement.